Pasithea Therapeutics Corp. — Investor Relations & Filings

Pasithea Therapeutics Corp. is a clinical-stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (CNS) disorders and RASopathies. The company develops new therapeutics for neurological and psychiatric conditions, with a primary focus on Neurofibromatosis type 1 (NF1), a disorder causing tumor growth along nerves, and Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. Its research also targets Multiple Sclerosis (MS), a chronic autoimmune disease of the CNS, and schizophrenia, a disabling psychiatric illness. The company's pipeline additionally includes treatments for solid tumors.